Merck Purchases Biotech Firm Afferent


Merck has announced the purchase of biotechnology firm Afferent Pharmaceuticals. The deal was completed with a $500 million upfront payment, and further milestones could lead to additional payments of up to $750 million. Afferent has a focus on neurogenic conditions, and is targeting the P2X3 receptor.

Read the source article at The Wall Street Journal

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>